Dynavax secures $175M to fuel Heplisav-B marketing, immuno-oncology trials

20th February 2018 Uncategorised 0

About a month after launching Heplisav-B in the U.S., Dynavax is putting big money behind the hepatitis B vaccine. Through an agreement with CRG LP, Dynavax could receive up to $175 million in a loan to support the vaccine’s commercialization.

More: Dynavax secures 5M to fuel Heplisav-B marketing, immuno-oncology trials
Source: fierce